OncoMatch/Clinical Trials/NCT05651932
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
Is NCT05651932 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1 trial studies multiple treatments including Cohort A1 & A2: KTX-1001 and Cohort B1 & B2: KTX-1001+Mezigdomide for multiple myeloma.
Treatment: Cohort A1 & A2: KTX-1001 · Cohort B1 & B2: KTX-1001+Mezigdomide · Cohort C1 & C2: KTX-1001 + Carfilzomib (KYPROLIS®) · Cohort D: KTX-1001+ pomalidomide (Pomalyst, Imnovid) — A Phase I study to evaluate the safety of a novel, orally available, selective, and potent small molecule inhibitor of the histone lysine methyl transferase MMSET (also known as NSD2/WHSC1) to prevent the dimethylation of H3K36 in adult patients with relapsed or refractory multiple myeloma (RRMM).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Multiple Myeloma
Biomarker criteria
Required: WHSC1 t(4;14)
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: proteasome inhibitor
Must have received: imid
Must have received: anti-cd38 antibody
Cannot have received: mezigdomide (mezigdomide)
Cannot have received: carfilzomib (carfilzomib)
Exception: only for patients enrolled in cohorts c1 and c2, in the immediate last prior line of therapy
Cannot have received: pomalidomide (pomalidomide)
Exception: only for patients enrolled in cohort d, in the immediate last prior line of therapy
Lab requirements
Blood counts
inadequate bone marrow function [excluded]
Kidney function
inadequate renal function [excluded]
Liver function
inadequate hepatic function [excluded]
Cardiac function
inadequate cardiac function [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- UCSF Medical Center - Hematology and Blood and Marrow Transplant Clinic · San Francisco, California
- Mayo Clinic Hospital - Florida · Jacksonville, Florida
- The Winship Cancer Institute of Emory University · Atlanta, Georgia
- Massachusetts General Hospital · Boston, Massachusetts
- Dana-Farber Cancer Institute · Boston, Massachusetts
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05651932 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior mezigdomide, carfilzomib, pomalidomide disqualifies patients from enrollment.
Does this trial require WHSC1?
Yes, WHSC1 t(4;14) is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages